Pharmatech   Report issue

For profit Phase 2 Phase 4
Founded: Denver CO United States (1987)
Status: Acquired by Caris Life Science (2019)

Organization Overview

First Clinical Trial
2000
NCT00026351
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Manyak, Michael, M.D. | Pharmatech Oncology

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Leukemia (Phase 4)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 4)

Leukemia, Lymphoid (Phase 4)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Prostatic Neoplasms (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 14